E Grande1, J Santamaría Sandi2, J Capdevila3, E Navarro González4, C Zafón Llopis5, T Ramón Y Cajal Asensio6, J M Gómez Sáez7, P Jiménez-Fonseca8, G Riesco-Eizaguirre9, J C Galofré10. 1. Servicio de Oncología Médica, Hospital Ramón y Cajal, Carretera de Colmenar km 9,1, 28034, Madrid, Spain. egrande@oncologiahrc.com. 2. Endocrinology and Nutrition Service, Hospital Universitario de Cruces, Vizcaya, Spain. 3. Medical Oncology Service, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 4. Endocrinology and Nutrition Service, Hospital Universitario Virgen del Rocio, Seville, Spain. 5. Endocrinology and Nutrition Service, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 6. Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 7. CIBERDEM, Endocrinology and Nutrition Service, Hospital Universitario de Bellvitge, Barcelona, Spain. 8. Medical Oncology Service, Hospital Universitario Central de Asturias, Oviedo, Spain. 9. Endocrinology and Nutrition Service, Hospital Universitario de Móstoles, Madrid, Spain. 10. Endocrinology and Nutrition Service, Clínica Universidad de Navarra, Pamplona, Spain.
Abstract
BACKGROUND: Of all thyroid cancers, <5 % are medullary (MTC). It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny. METHODS: The electronic search was conducted using MEDLINE (PubMed), EMBASE and Cochrane Central Register of Controlled Trials. Quality assessments of selected current articles, guidelines and reviews of MTC were performed. RESULTS: This consensus updates and summarizes biology, treatment and prognostic considerations of MTC. CONCLUSIONS: Multidisciplinary teams and specialized centers are recommended for the management of MTC patients. In the metastatic setting, those patients with large volume of disease are candidates to start systemic treatment mainly if they are symptomatic and the tumor has progressed in the last 12-14 months. Wait and see strategy should be offered to patients with: disseminated disease with only high levels of calcitonin and no macroscopic structural disease, low burden and absence of progression.
BACKGROUND: Of all thyroid cancers, <5 % are medullary (MTC). It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny. METHODS: The electronic search was conducted using MEDLINE (PubMed), EMBASE and Cochrane Central Register of Controlled Trials. Quality assessments of selected current articles, guidelines and reviews of MTC were performed. RESULTS: This consensus updates and summarizes biology, treatment and prognostic considerations of MTC. CONCLUSIONS: Multidisciplinary teams and specialized centers are recommended for the management of MTC patients. In the metastatic setting, those patients with large volume of disease are candidates to start systemic treatment mainly if they are symptomatic and the tumor has progressed in the last 12-14 months. Wait and see strategy should be offered to patients with: disseminated disease with only high levels of calcitonin and no macroscopic structural disease, low burden and absence of progression.
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: J Fromigué; T De Baere; E Baudin; C Dromain; S Leboulleux; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2006-04-11 Impact factor: 5.958
Authors: Mauro Papotti; Martina Olivero; Marco Volante; Francesco Negro; Maria Prat; Paolo M. Comoglio; Maria Flavia DiRenzo Journal: Endocr Pathol Date: 2000 Impact factor: 3.943